Andrew P. Mazar PhD

Dr. Mazar has spent twenty-eight years working on drug discovery and development at the interface of academia and industry and has founded or co-founded eight start-up companies including Tactic Pharma to commercialize new drug discoveries. He is internationally recognized for his translational research on the role of the urokinase plasminogen activator (uPA) system in tumor progression as well as mechanisms of cancer invasion and metastasis. Prior to his roles as a faculty member in the Chemistry of Life Processes Institute and the Department of Pharmacology, Feinberg School of Medicine at Northwestern University and co-founding Tactic Pharma in 2010, Dr. Mazar was the Chief Scientific Officer at Attenuon, LLC in San Diego from 2000 to 2009 and led discovery and development efforts resulting in three drugs entering oncology clinical trials. Dr. Mazar has now overseen 18 IND enabling efforts, many of these focused on drugs discovered in academia.